Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Amornsupak, Kamolporn ^a   Insawang, Tonkla ^a   Thuwajit, Peti ^a   O Charoenrat, Pornchai ^a   Eccles, Suzanne A ^b   Thuwajit, Chanitra ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; Cancer associated fibroblast; Chemoresistance; HMGB1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYTOKERATIN 19; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; NEUTRALIZING ANTIBODY; ACTA2 PROTEIN, HUMAN; ACTIN; ANTIBODY; ANTINEOPLASTIC ANTIBIOTIC; CULTURE MEDIUM; RECOMBINANT PROTEIN; TUMOR PROTEIN;

ARTICLE; AUTOPHAGY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CELL MIGRATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ACTINS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES; AUTOPHAGY; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; HMGB1 PROTEIN; HUMANS; KERATIN-19; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84924744513     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-955     Document Type: Article

References (57)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011,61(2):69-90. 10.3322/caac.20107
2. Attasara P, Buasom R: Hospital-based cancer registry 2010. Natl Cancer Inst Thai 2010, 24:1-52.
3. Hernandez-Aya LF, Gonzalez-Angulo AM: Adjuvant systemic therapies in breast cancer. Surg Clin North Am 2013,93(2):473-491. 10.1016/j.suc.2012.12.002
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22. 10.1007/978-0-387-74039-3_1
5. Sebens S, Schafer H: The tumor stroma as mediator of drug resistance-a potential target to improve cancer therapy? Curr Pharm Biotechnol 2012,13(11):2259-2272. 10.2174/138920112802501999
6. Franco OE, Shaw AK, Strand DW, Hayward SW: Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010,21(1):33-39. 10.1016/j.semcdb.2009.10.010
7. Thibault B, Castells M, Delord JP, Couderc B: Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev 2014,33(1):17-39. 10.1007/s10555-013-9456-2
8. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C: Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer 2010, 9:13. 10.1186/1476-4598-9-13
9. Muerkoster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, Tsao MS, Folsch UR, Schafer H: Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases. Int J Cancer 2008,123(8):1751-1760. 10.1002/ijc.23703
10. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, Sebens T, Kloppel G, Kalthoff H, Folsch UR, Schafer H: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004,64(4):1331-1337. 10.1158/0008-5472.CAN-03-1860
11. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004,6(1):17-32. 10.1016/j.ccr.2004.06.010
12. Hasebe T, Sasaki S, Imoto S, Ochiai A: Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000,156(5):1701-1710. 10.1016/S0002-9440(10)65041-9
13. Hasebe T, Sasaki S, Imoto S, Ochiai A: Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 2001,14(4):325-337. 10.1038/modpathol.3880310
14. Busch S, Acar A, Magnusson Y, Gregersson P, Ryden L, Landberg G: TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 2013. doi: 10.1038/onc.2013.527
15. Mao Y, Keller ET, Garfield DH, Shen K, Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013,32(1-2):303-315.
16. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009,15(1):68-74. 10.1038/nm.1908
17. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006,116(7):1955-1962. 10.1172/JCI26532
18. Shekhar MP, Santner S, Carolin KA, Tait L: Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007,170(5):1546-1560. 10.2353/ajpath.2007.061004
19. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP: Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011,12(10):924-938. 10.4161/cbt.12.10.17780
20. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388. 10.1146/annurev.immunol.021908.132603
21. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007,13(10):2836-2848. 10.1158/1078-0432.CCR-06-1953
22. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ3rd: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007,30(6):596-606. 10.1097/CJI.0b013e31804efc76
23. Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ 3rd, Lotze MT: Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007,81(1):75-83.
24. Lee H, Song M, Shin N, Shin CH, Min BS, Kim HS, Yoo JS, Kim H: Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 2012,7(4):e34318. 10.1371/journal.pone.0034318
25. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H: Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012,72(13):3290-3301. 10.1158/0008-5472.CAN-11-3481
26. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007,13(9):1050-1059. 10.1038/nm1622
27. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999,285(5425):248-251. 10.1126/science.285.5425.248
28. Bartling B, Fuchs C, Silber RE, Simm A: Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors. Int J Mol Med 2007,20(2):217-224.
29. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H: High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 2013,49(3):741-751. 10.1016/j.ejca.2012.09.016
30. Xing F, Saidou J, Watabe K: Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010, 15:166-179. 10.2741/3613
31. Castells M, Thibault B, Delord JP, Couderc B: Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 2012,13(8):9545-9571.
32. Tiago M, Oliveira EM, Brohem CA, Pennacchi PC, Paes RD, Haga RB, Campa A, Barros SB, Smalley KS, Silvya ME: Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng Part A 2014,20(17-18):2412-2421.
33. Nakagawa H, Liyanarachchi S, Davuluri RV, Auer H, Martin EW Jr, de la Chapelle A, Frankel WL: Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004,23(44):7366-7377. 10.1038/sj.onc.1208013
34. Al-Rakan MA, Colak D, Hendrayani SF, Al-Bakheet A, Al-Mohanna FH, Kaya N, Al-Malik O, Aboussekhra A: Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol 2013,231(4):457-465. 10.1002/path.4256
35. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008,68(4):989-997. 10.1158/0008-5472.CAN-07-2017
36. Jeong H, Ryu YJ, An J, Lee Y, Kim A: Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 2012,60(6B):E87-E95. 10.1111/j.1365-2559.2012.04195.x
37. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C: Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 2009,21(4):957-969.
38. Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T, Nakano T: Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 2013, 13:205. 10.1186/1471-2407-13-205
39. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A: High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012,55(6):1863-1875. 10.1002/hep.25572
40. Willenbrock S, Braun O, Baumgart J, Lange S, Junghanss C, Heisterkamp A, Nolte I, Bullerdiek J, Murua Escobar H: TNF-alpha induced secretion of HMGB1 from non-immune canine mammary epithelial cells (MTH53A). Cytokine 2012,57(2):210-220. 10.1016/j.cyto.2011.11.011
41. Hao Q, Du XQ, Fu X, Tian J: Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2008,30(4):292-295.
42. Wild CA, Brandau S, Lotfi R, Mattheis S, Gu X, Lang S, Bergmann C: HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012,48(5):409-416. 10.1016/j.oraloncology.2011.12.009
43. Wu D, Ding Y, Wang S, Zhang Q, Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008,216(2):167-175. 10.1002/path.2391
44. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 2008,49(6):1184-1189. 10.1080/10428190802064909
45. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008,47(1):56-63. 10.1002/gcc.20505
46. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J: Variation of HMGB1 expression in breast cancer. Anticancer Res 2001,21(6A):3881-3885.
47. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003,17(10):1295-1297.
48. Kostova N, Zlateva S, Ugrinova I, Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010,337(1-2):251-258.
49. Todorova J, Pasheva E: High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 2012,3(1):214-218.
50. Ranzato E, Patrone M, Pedrazzi M, Burlando B: Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem Biophys 2010,57(1):9-17. 10.1007/s12013-010-9077-0
51. Hou CH, Fong YC, Tang CH: HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-kappaB pathways. J Cell Physiol 2011,226(8):2006-2015. 10.1002/jcp.22541
52. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, Tang D, Cao L: DAMP-mediated autophagy contributes to drug resistance. Autophagy 2011,7(1):112-114. 10.4161/auto.7.1.14005
53. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, Tang D, Cao L: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011,25(1):23-31. 10.1038/leu.2010.225
54. Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res 2014,20(12):3159-3173. 10.1158/1078-0432.CCR-13-2060
55. Smolarczyk R, Cichon T, Matuszczak S, Mitrus I, Lesiak M, Kobusinska M, Kamysz W, Jarosz M, Sieron A, Szala S: The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp (Warsz) 2012,60(5):391-399. 10.1007/s00005-012-0183-0
56. Guerriero JL, Ditsworth D, Catanzaro JM, Sabino G, Furie MB, Kew RR, Crawford HC, Zong WX: DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol 2011,186(6):3517-3526. 10.4049/jimmunol.1003267
57. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S: Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol 2013,34(1):81-90. 10.1007/s13277-012-0513-1